Market capitalization | $2.11m |
Enterprise Value | $1.71m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.55 |
P/S ratio (TTM) P/S ratio | 0.67 |
P/B ratio (TTM) P/B ratio | 0.24 |
Revenue growth (TTM) Revenue growth | 39.68% |
Revenue (TTM) Revenue | $3.13m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a SiNtx Technologies, Inc. forecast:
2 Analysts have issued a SiNtx Technologies, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3.13 3.13 |
40%
40%
|
|
Gross Profit | 0.38 0.38 |
36%
36%
|
|
EBITDA | -11 -11 |
8%
8%
|
EBIT (Operating Income) EBIT | -12 -12 |
4%
4%
|
Net Profit | -8.60 -8.60 |
9%
9%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SINTX Technologies, Inc. operates as a commercial biomaterial company. It focuses on using silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The firm markets spinal fusion products and develops products for use in total hip and knee joint replacements. Its FDA-cleared and CE-marked spine products are marketed in the U.S. and selected markets in Europe and South America. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in 1996 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Eric Olson |
Employees | 43 |
Founded | 1996 |
Website | www.sintx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.